Hypertension prevalence among the male population aged 35-74 years in Novosibirsk

Aim. To study the prevalence and risk factors of hypertension (HTN), structure and effectiveness of treatment coverage, as well as disease control indicators among the male population aged 35-74 years in Novosibirsk.

Material and methods. This cross-sectional study of the Novosibirsk population was conducted in 2021-2023 at the Research Institute for Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics according to the ESSE-RF3 study protocol. A total of 1200 people aged 35-74 years living in Novosibirsk were examined. The analysis included 600 men. The response rate exceeded 70%. HTN was considered detected in systolic blood pressure (BP) ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or in patients taking antihypertensive agents. Awareness was estimated as the proportion of individuals who had previously been informed by a physician about HTN. Treatment effectiveness was considered the proportion of individuals who achieved target BP values while taking antihypertensive therapy. Hypertension control was considered the proportion of individuals who achieved target values among all those examined with HTN. Statistical processing was performed using the SPSS software package (version 13.0). Associations were assessed using multiple logistic regression analysis. The critical significance level of the null hypothesis (p) was 0,05.

Results. The medians of systolic and diastolic BP among men in No­vo­sibirsk were 136,0 [126,5; 149,5] and 89,0 [82,0; 95,5] mm Hg, respectively. The prevalence of HTN among men aged 35-74 in Novo­sibirsk was 68,9%, while 81,1% of men in Novosibirsk were aware of HTN. Among men with HTN, 54,7% take antihypertensive agents. The effectiveness of treatment among men in Novosibirsk is 32,3%, while 19,6% of men control the disease. The odds of hypertension occurrence in men with hypertriglyceridemia increased by 3,5 times, with abdominal obesity — by 2 times, with an positive family history for cardiovascular diseases — by 1,6 times, and with each year of life increased by 1,1 times.

Conclusion. The prevalence of HTN among men in Novosibirsk is higher in comparison with the average Russian level. Significant risk factors for HTN include abdominal obesity, hypertriglyceridemia, and decreased physical activity. While awareness, treatment coverage, and HTN control among men aged 35-74 in Novosibirsk correspond to Russian trends, treatment effectiveness turned out to be slightly lower than in the Russian population.

1. GBD 2017 Risk Factor Collaborators. Global, regional, and na­tional comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923-94. doi:10.1016/S0140-6736(18)32225-6.

2. Joseph P, Kutty VR, Mohan V, et al. Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. Eur Heart J. 2022;43(30):2831-40. doi:10.1093/eurheartj/ehac249.

3. Li S, Liu Z, Joseph P, et al. on behalf of the PURE-China In­vestigators. Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy. Eur Heart J. 2022;43(30):2852-63. doi:10.1093/eurheartj/ehac268.

4. Lopez-Jaramillo P, Joseph P, Lopez-Lopez JP, et al. Risk factors, cardiovascular disease, and mortality in South America: a PURE sub­study. Eur Heart J. 2022;43(30):2841-51. doi:10.1093/eurheartj/ehac113.

5. Zhou B, Perel P, Mensah GA, et al. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. doi:10.1038/s41569-021-00559-8.

6. Schutte AE, Jafar TH, Poulter NR, et al. Addressing global dis­parities in blood pressure control: perspectives of the Inter­national Society of Hypertension. Cardiovasc Res. 2023;119(2): 381-409. doi:10.1093/cvr/cvac130.

7. Drapkina OM, Shalnova SA, Imaeva AE, et al. Epidemiology of Car­diovascular Diseases in Regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardio­vascular Therapy and Prevention. 2022;21(5):3246. (In Russ.) doi:10.15829/1728-8800-2022-3246.

8. Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Cli­nical guidelines. Consilium Medicum. 2021;23(4):311-25. (In Russ.) doi:10.26442/20751753.2021.4.200832.

9. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Da­ta from the ESSE-RF3 study. Cardiovascular Therapy and Preven­tion. 2023;22(8S):3785. (In Russ.) doi:10.15829/1728-8800-2023-3785.

10. Pajak A, Kuulasmaa K, Tuomilehto J, et al. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA Project. World Health Stat Q. 1988;41(3-4):115-40.

11. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hyper­tension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.). doi:10.15829/1728-8800-2014-4-4-14.

12. Balanova YuA, Shalnova S, Imaeva AE, et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-66. (In Russ.) doi:10.20996/1819-6446-2019-15-4-450-466.

13. Grinshtein YuI, Petrova MM, Shabalin VV, et al. The prevalence of arterial hypertension in Krasnoyarsky territory: the data from the epidemiology study ESSE-RF. Arterial’naya Gipertenziya (Arterial Hypertension). 2016;22(6):551-9. (In Russ.) doi:10.18705/1607-419X-2016-22-6-551-559.

14. Chazova IE, Trubacheva IA, Zhernakova YuV, et al. The prevalence of arterial hypertension as a risk factor of cardiovascular diseases in one of the cities in Siberian Federal District. Systemic Hypertension. 2013;10(4):30-7. (In Russ.)

15. Simonova G, Nikitin Yu, Glushanina O, et al. Arterial hypertension and the risk of cardiovascular mortality in an urban Siberian popu­lation. The Siberian Scientific Medical Journal. 2006;4(122):88-92. (In Russ.)

16. Malyutina SK, Denisova D, Bobak M, et al. 30-year trends in hypertension prevalence, awareness and control in a definite Russian population by six large-scale surveys of 24,000 subjects. Eur Heart J. 2018;39(suppl_1):ehy565.P1276. doi:10.1093/eurheartj/ehy565.P1276.

17. Xu X, Bao H, Tian Z, et al. Prevalence, awareness, treatment, and control of hypertension in Northern China: a cross-sectional study. BMC Cardiovasc Disord. 2021;21(1):525. doi:10.1186/s12872-021-02333-7.

18. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639-51. doi:10.1016/S0140-6736(19)31145-6.

19. Malyutina SK, Mazdorova EV, Shapkina MYu, et al. Profile of antihypertensive therapy and control of arterial hypertension in the population. In: Epidemiology of arterial hypertension in Siberia. Novosibirsk: Nauka. 2024:21-30. (In Russ.) ISBN: 978-5-02-041520-1.

20. Balanova YuA, Shalnova SA, Kutsenko VA, et al. Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study. Rational Pharmacotherapy in Cardiology. 2024;20(1):4-12. (In Russ.). doi:10.20996/1819-6446-2024-3010.

21. Grinshtein YI, Petrova MM, Shabalin VV, et al. What drugs do hypertension patients take in clinical practice? Structure of antihypertensive drugs in a large siberian region. Meditsinskiy sovet = Medical Council. 2016;(17):24-7. (In Russ.). doi:10.21518/2079-701X-2016-17-24-27.

22. Chazova IE, Ratova LG, Boytsov SA, et al. Diagnostics and treatment of arterial hypertension. Russian recommendations (fourth revision). Journal Systemic hypertension. 2010;3:5-26. (In Russ.)

23. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Car­diology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

24. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.